$VCYT
Veracyte Inc Stock $vcyt

$vcyt Overview Financials Valuation SEC Filings Company Website

2020 Q1 Form 10-Q Financial Statement

#000138410120000058 Filed on May 06, 2020

Income Statement

Concept	2020 Q1	2019 Q1
Revenue	$31.12M	$29.53M
YoY Change	5.39%	47.34%
Cost Of Revenue	$12.24M	$8.513M
YoY Change	43.78%	8.21%
Gross Profit	$18.88M	$21.02M
YoY Change	-10.16%	72.63%
Gross Profit Margin	60.66%	71.17%
Selling, General & Admin	$25.40M	$19.38M
YoY Change	31.04%	12.77%
% of Gross Profit	134.52%	92.22%
Research & Development	$4.407M	$3.435M
YoY Change	28.3%	-6.53%
% of Gross Profit	23.34%	16.34%
Depreciation & Amortization	$1.972M	$945.0K
YoY Change	108.68%	-3.57%
% of Gross Profit	10.44%	4.5%
Operating Expenses	$29.80M	$22.82M
YoY Change	30.63%	9.37%
Operating Profit	-$12.20M	-$2.067M
YoY Change	490.23%	-76.92%
Interest Expense	$55.00K	$303.0K
YoY Change	-81.85%	-32.37%
% of Operating Profit
Other Income/Expense, Net	$539.0K	$453.0K
YoY Change	18.98%	100.44%
Pretax Income	-$11.72M	-$1.920M
YoY Change	510.21%	-79.08%
Income Tax	$0.00
% Of Pretax Income
Net Earnings	-$11.72M	-$1.917M
YoY Change	511.16%	-79.12%
Net Earnings / Revenue	-37.65%	-6.49%
Basic Earnings Per Share
Diluted Earnings Per Share	-$235.4K	-$46.64K
COMMON SHARES
Basic Shares Outstanding	49.74M shares	41.11M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2020 Q1	2019 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$153.1M	$67.80M
YoY Change	125.81%	149.26%
Cash & Equivalents	$153.1M	$67.84M
Short-Term Investments
Other Short-Term Assets	$3.000M	$2.400M
YoY Change	25.0%	14.29%
Inventory	$6.094M	$3.768M
Prepaid Expenses
Receivables	$19.09M	$16.62M
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$181.4M	$90.62M
YoY Change	100.14%	92.6%
LONG-TERM ASSETS
Property, Plant & Equipment	$8.788M	$8.114M
YoY Change	8.31%	-11.95%
Goodwill	$2.725M	$1.057M
YoY Change	157.81%	0.0%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$1.302M	$1.049M
YoY Change	24.12%	125.11%
Total Long-Term Assets	$85.74M	$32.92M
YoY Change	160.44%	36.37%
TOTAL ASSETS
Total Short-Term Assets	$181.4M	$90.62M
Total Long-Term Assets	$85.74M	$32.92M
Total Assets	$267.1M	$123.5M
YoY Change	116.21%	73.53%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$7.665M	$4.064M
YoY Change	88.61%	21.1%
Accrued Expenses	$10.08M	$8.788M
YoY Change	14.69%	3.6%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due		$0.00
YoY Change
Total Short-Term Liabilities	$19.19M	$14.33M
YoY Change	33.95%	21.03%
LONG-TERM LIABILITIES
Long-Term Debt	$748.0K	$12.85M
YoY Change	-94.18%	-48.62%
Other Long-Term Liabilities	$16.70M	$12.60M
YoY Change	32.54%	207.32%
Total Long-Term Liabilities	$748.0K	$12.85M
YoY Change	-94.18%	-48.62%
TOTAL LIABILITIES
Total Short-Term Liabilities	$19.19M	$14.33M
Total Long-Term Liabilities	$748.0K	$12.85M
Total Liabilities	$36.68M	$39.77M
YoY Change	-7.76%	-3.44%
SHAREHOLDERS EQUITY
Retained Earnings	-$258.4M	-$236.0M
YoY Change	9.49%	7.15%
Common Stock	$488.8M	$319.8M
YoY Change	52.86%	27.77%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$230.4M	$83.77M
YoY Change
Total Liabilities & Shareholders Equity	$267.1M	$123.5M
YoY Change	116.21%	73.53%

Cashflow Statement

Concept	2020 Q1	2019 Q1
OPERATING ACTIVITIES
Net Income	-$11.72M	-$1.917M
YoY Change	511.16%	-79.12%
Depreciation, Depletion And Amortization	$1.972M	$945.0K
YoY Change	108.68%	-3.57%
Cash From Operating Activities	-$5.301M	-$1.011M
YoY Change	424.33%	-86.36%
INVESTING ACTIVITIES
Capital Expenditures	$665.0K	$765.0K
YoY Change	-13.07%	237.0%
Acquisitions	$0.00
YoY Change
Other Investing Activities	$0.00	$20.00K
YoY Change	-100.0%
Cash From Investing Activities	-$665.0K	-$749.0K
YoY Change	-11.21%	229.96%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net	$0.00	$12.50M
YoY Change	-100.0%
Cash From Financing Activities	-$219.0K	-$8.394M
YoY Change	-97.39%	-1031.63%
NET CHANGE
Cash From Operating Activities	-$5.301M	-$1.011M
Cash From Investing Activities	-$665.0K	-$749.0K
Cash From Financing Activities	-$219.0K	-$8.394M
Net Change In Cash	-$6.185M	-$10.15M
YoY Change	-39.09%	50.68%
FREE CASH FLOW
Cash From Operating Activities	-$5.301M	-$1.011M
Capital Expenditures	$665.0K	$765.0K
Free Cash Flow	-$5.966M	-$1.776M
YoY Change	235.92%	-76.75%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2020Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001384101
CY2020Q1	dei	Amendment Flag AmendmentFlag	false
CY2020Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2020Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2020
CY2020Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2020Q1	dei	Document Type DocumentType	10-Q
CY2020Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2020Q1	dei	Document Period End Date DocumentPeriodEndDate	2020-03-31
CY2020Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2020Q1	dei	Entity File Number EntityFileNumber	001-36156
CY2020Q1	dei	Entity Registrant Name EntityRegistrantName	VERACYTE, INC.
CY2020Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2020Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	20-5455398
CY2020Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	6000 Shoreline Court
CY2020Q1	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 300
CY2020Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	South San Francisco
CY2020Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2020Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	94080
CY2020Q1	dei	City Area Code CityAreaCode	650
CY2020Q1	dei	Local Phone Number LocalPhoneNumber	243-6300
CY2020Q1	dei	Security12b Title Security12bTitle	Common Stock, par value, $0.001 per share
CY2020Q1	dei	Trading Symbol TradingSymbol	VCYT
CY2020Q1	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2020Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2020Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2020Q1	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2020Q1	dei	Entity Small Business EntitySmallBusiness	false
CY2020Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2020Q1	dei	Entity Shell Company EntityShellCompany	false
CY2020Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	50053437	shares
CY2020Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	153132000	USD
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	159317000	USD
CY2020Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	19091000	USD
CY2019Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	19329000	USD
CY2020Q1	us-gaap	Inventory Net InventoryNet	6094000	USD
CY2019Q4	us-gaap	Inventory Net InventoryNet	6806000	USD
CY2020Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3045000	USD
CY2019Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2235000	USD
CY2020Q1	us-gaap	Assets Current AssetsCurrent	181362000	USD
CY2019Q4	us-gaap	Assets Current AssetsCurrent	187687000	USD
CY2020Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	8788000	USD
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	8933000	USD
CY2020Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	8576000	USD
CY2019Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	8808000	USD
CY2020Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	63744000	USD
CY2019Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	65019000	USD
CY2020Q1	us-gaap	Goodwill Goodwill	2725000	USD
CY2019Q4	us-gaap	Goodwill Goodwill	2725000	USD
CY2020Q1	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	603000	USD
CY2019Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	603000	USD
CY2020Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1302000	USD
CY2019Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1437000	USD
CY2020Q1	us-gaap	Assets Assets	267100000	USD
CY2019Q4	us-gaap	Assets Assets	275212000	USD
CY2020Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	7665000	USD
CY2019Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2328000	USD
CY2020Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	10079000	USD
CY2019Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	13734000	USD
CY2020Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1450000	USD
CY2019Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1407000	USD
CY2020Q1	us-gaap	Liabilities Current LiabilitiesCurrent	19194000	USD
CY2019Q4	us-gaap	Liabilities Current LiabilitiesCurrent	17469000	USD
CY2020Q1	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	748000	USD
CY2019Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	694000	USD
CY2020Q1	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	5604000	USD
CY2019Q4	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	6088000	USD
CY2020Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	11132000	USD
CY2019Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	11506000	USD
CY2020Q1	us-gaap	Liabilities Liabilities	36678000	USD
CY2019Q4	us-gaap	Liabilities Liabilities	35757000	USD
CY2020Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2019Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2020Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2019Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2020Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2019Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2019Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2020Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2020Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2019Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2020Q1	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2019Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2020Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2019Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2019Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	125000000	shares
CY2020Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	125000000	shares
CY2020Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	49999923	shares
CY2020Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	49999923	shares
CY2019Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	49625341	shares
CY2019Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	49625341	shares
CY2020Q1	us-gaap	Common Stock Value CommonStockValue	50000	USD
CY2019Q4	us-gaap	Common Stock Value CommonStockValue	50000	USD
CY2020Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	488773000	USD
CY2019Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	486090000	USD
CY2020Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-258401000	USD
CY2019Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-246685000	USD
CY2020Q1	us-gaap	Stockholders Equity StockholdersEquity	230422000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	239455000	USD
CY2020Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	267100000	USD
CY2019Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	275212000	USD
CY2020Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	31122000	USD
CY2019Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	29529000	USD
CY2019Q1	us-gaap	Cost Of Revenue CostOfRevenue	8513000	USD
CY2020Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4407000	USD
CY2019Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3435000	USD
CY2020Q1	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	17584000	USD
CY2019Q1	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	12477000	USD
CY2020Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	7813000	USD
CY2019Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	6904000	USD
CY2020Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1275000	USD
CY2019Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	267000	USD
CY2020Q1	us-gaap	Costs And Expenses CostsAndExpenses	43322000	USD
CY2019Q1	us-gaap	Costs And Expenses CostsAndExpenses	31596000	USD
CY2020Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-12200000	USD
CY2019Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-2067000	USD
CY2020Q1	us-gaap	Interest Expense InterestExpense	55000	USD
CY2019Q1	us-gaap	Interest Expense InterestExpense	303000	USD
CY2020Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	539000	USD
CY2019Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	453000	USD
CY2020Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-11716000	USD
CY2020Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-11716000	USD
CY2019Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-1917000	USD
CY2019Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-1917000	USD
CY2020Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.24
CY2019Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.05
CY2020Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	49792631	shares
CY2019Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	41168593	shares
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	239455000	USD
CY2020Q1	vcyt	Sharebased Compensation Arrangementby Sharebased Payment Award Value Optionsand Non Option Equity Instruments Exercisesin Period SharebasedCompensationArrangementbySharebasedPaymentAwardValueOptionsandNonOptionEquityInstrumentsExercisesinPeriod	981000	USD
CY2020Q1	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	1101000	USD
CY2020Q1	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	2304000	USD
CY2020Q1	vcyt	Adjustments To Additional Paid In Capital Share Based Compensation Employee AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployee	2551000	USD
CY2020Q1	vcyt	Adjustments To Additional Paid In Capital Share Based Compensation Espp AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationESPP	354000	USD
CY2020Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-11716000	USD
CY2020Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-11716000	USD
CY2020Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-11716000	USD
CY2020Q1	us-gaap	Stockholders Equity StockholdersEquity	230422000	USD
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	79755000	USD
CY2019Q1	vcyt	Sharebased Compensation Arrangementby Sharebased Payment Award Value Optionsand Non Option Equity Instruments Exercisesin Period SharebasedCompensationArrangementbySharebasedPaymentAwardValueOptionsandNonOptionEquityInstrumentsExercisesinPeriod	4240000	USD
CY2019Q1	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	491000	USD
CY2019Q1	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	556000	USD
CY2019Q1	vcyt	Adjustments To Additional Paid In Capital Share Based Compensation Employee AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployee	1598000	USD
CY2019Q1	vcyt	Adjustments To Additional Paid In Capital Share Based Compensation Non Employee AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationNonEmployee	20000	USD
CY2019Q1	vcyt	Adjustments To Additional Paid In Capital Share Based Compensation Espp AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationESPP	141000	USD
CY2019Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-1917000	USD
CY2019Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-1917000	USD
CY2019Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-1917000	USD
CY2019Q1	us-gaap	Stockholders Equity StockholdersEquity	83772000	USD
CY2020Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-11716000	USD
CY2019Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-1917000	USD
CY2020Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1972000	USD
CY2019Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	945000	USD
CY2020Q1	us-gaap	Disposal Group Not Discontinued Operation Gain Loss On Disposal DisposalGroupNotDiscontinuedOperationGainLossOnDisposal	0	USD
CY2019Q1	us-gaap	Disposal Group Not Discontinued Operation Gain Loss On Disposal DisposalGroupNotDiscontinuedOperationGainLossOnDisposal	16000	USD
CY2020Q1	us-gaap	Share Based Compensation ShareBasedCompensation	2905000	USD
CY2019Q1	us-gaap	Share Based Compensation ShareBasedCompensation	1759000	USD
CY2020Q1	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	0	USD
CY2019Q1	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	8000	USD
CY2020Q1	vcyt	Interest Expenseand Prepayment Penalty InterestExpenseandPrepaymentPenalty	54000	USD
CY2019Q1	vcyt	Interest Expenseand Prepayment Penalty InterestExpenseandPrepaymentPenalty	64000	USD
CY2020Q1	vcyt	Inventory Reserve Effect On Income Net InventoryReserveEffectOnIncomeNet	1088000	USD
CY2019Q1	vcyt	Inventory Reserve Effect On Income Net InventoryReserveEffectOnIncomeNet	0	USD
CY2020Q1	vcyt	Noncash Lease Expenses NoncashLeaseExpenses	232000	USD
CY2019Q1	vcyt	Noncash Lease Expenses NoncashLeaseExpenses	212000	USD
CY2020Q1	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-484000	USD
CY2019Q1	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	0	USD
CY2020Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-238000	USD
CY2019Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	3447000	USD
CY2020Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	376000	USD
CY2019Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	366000	USD
CY2020Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	818000	USD
CY2019Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	11000	USD
CY2020Q1	vcyt	Increase Decrease Operating Lease Right Of Use Asset Lease Liability IncreaseDecreaseOperatingLeaseRightOfUseAssetLeaseLiability	331000	USD
CY2019Q1	vcyt	Increase Decrease Operating Lease Right Of Use Asset Lease Liability IncreaseDecreaseOperatingLeaseRightOfUseAssetLeaseLiability	292000	USD
CY2020Q1	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-135000	USD
CY2019Q1	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-37000	USD
CY2020Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	5450000	USD
CY2019Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1726000	USD
CY2020Q1	vcyt	Increase Decrease In Accrued Liabilities And Deferred Rent IncreaseDecreaseInAccruedLiabilitiesAndDeferredRent	-3650000	USD
CY2019Q1	vcyt	Increase Decrease In Accrued Liabilities And Deferred Rent IncreaseDecreaseInAccruedLiabilitiesAndDeferredRent	287000	USD
CY2020Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-5301000	USD
CY2019Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1011000	USD
CY2020Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	665000	USD
CY2019Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	765000	USD
CY2020Q1	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	0	USD
CY2019Q1	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	16000	USD
CY2020Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-665000	USD
CY2019Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-749000	USD
CY2020Q1	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	0	USD
CY2019Q1	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	12500000	USD
CY2020Q1	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	0	USD
CY2019Q1	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	75000	USD
CY2020Q1	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	2304000	USD
CY2019Q1	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	556000	USD
CY2020Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	2085000	USD
CY2019Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	4737000	USD
CY2020Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-219000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	159920000	USD
CY2019Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-8394000	USD
CY2020Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-6185000	USD
CY2019Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-10154000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	159920000	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	78598000	USD
CY2020Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	153735000	USD
CY2019Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	68444000	USD
CY2020Q1	vcyt	Capital Expenditures Incurred But Not Yet Paid Net CapitalExpendituresIncurredButNotYetPaidNet	113000	USD
CY2019Q1	vcyt	Capital Expenditures Incurred But Not Yet Paid Net CapitalExpendituresIncurredButNotYetPaidNet	95000	USD
CY2020Q1	us-gaap	Interest Paid Net InterestPaidNet	1000	USD
CY2019Q1	us-gaap	Interest Paid Net InterestPaidNet	228000	USD
CY2020Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	153132000	USD
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	159317000	USD
CY2020Q1	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	603000	USD
CY2019Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	603000	USD
CY2020Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	153735000	USD
CY2020Q1	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2019Q2	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	9200000	USD
CY2020Q1	vcyt	Number Of Disease Areas With Genomic Testing NumberOfDiseaseAreasWithGenomicTesting	4	diseaseAreas
CY2019Q1	us-gaap	Prior Period Reclassification Adjustment PriorPeriodReclassificationAdjustment	212000	USD
CY2020Q1	us-gaap	Use Of Estimates UseOfEstimates	<div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">Use of Estimates</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The preparation of unaudited interim financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities as of the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Items subject to such estimates include: revenue recognition; write-down of supplies; the useful lives of property and equipment; the recoverability of long-lived assets; the incremental borrowing rate for leases; the estimation of the fair value of intangible assets and contingent consideration; stock options; income tax uncertainties, including a valuation allowance for deferred tax assets; and contingencies. The Company bases these estimates on historical and anticipated results, trends, and various other assumptions that the Company believes are reasonable under the circumstances, including assumptions as to future events. These estimates form the basis for making judgments about the carrying values of assets and liabilities and recorded revenue and expenses that are not readily apparent from other sources. Actual results could differ from those estimates and assumptions.</span></div>
CY2019Q2	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	6325000	shares
CY2019Q2	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	23.25
CY2019Q2	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	137800000	USD
CY2020Q1	vcyt	Percentof Principal Amount Needed To Be Collateralized By U.S.Treasuryand Agency Securities PercentofPrincipalAmountNeededToBeCollateralizedByU.S.TreasuryandAgencySecurities	1.02
CY2020Q1	vcyt	Number Of Major Financial Institutions With Which Cash And Cash Equivalents Deposited NumberOfMajorFinancialInstitutionsWithWhichCashAndCashEquivalentsDeposited	1	financial_institution
CY2020Q1	vcyt	Numberof Tissue Sample Deliveries NumberofTissueSampleDeliveries	0	delivery
CY2020Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5716509	shares
CY2019Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	6235250	shares
CY2020Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	7497000	USD
CY2019Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	10100000	USD
CY2020Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	2582000	USD
CY2019Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	3634000	USD
CY2020Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	10079000	USD
CY2019Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	13734000	USD
CY2020Q1	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	1760000	USD
CY2020Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	2401000	USD
CY2020Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	2472000	USD
CY2020Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	2543000	USD
CY2020Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	2614000	USD
CY2020Q1	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	4227000	USD
CY2020Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	16017000	USD
CY2020Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	3435000	USD
CY2020Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	12582000	USD
CY2020Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1450000	USD
CY2020Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	11132000	USD
CY2020Q1	us-gaap	Operating Lease Expense OperatingLeaseExpense	474000	USD
CY2019Q1	us-gaap	Operating Lease Expense OperatingLeaseExpense	476000	USD
CY2020Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	5988461	shares
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	5562484	shares
CY2020Q1	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	9300887	shares
CY2019Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	7690456	shares

Files In Submission

Name	View Source	Status
0001384101-20-000058-index-headers.html	Edgar Link	pending
0001384101-20-000058-index.html	Edgar Link	pending
0001384101-20-000058.txt	Edgar Link	pending
0001384101-20-000058-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
vcyt-03312020xex311.htm	Edgar Link	pending
vcyt-03312020xex312.htm	Edgar Link	pending
vcyt-03312020xex321.htm	Edgar Link	pending
vcyt-03312020xex322.htm	Edgar Link	pending
vcyt-20200331.htm	Edgar Link	pending
vcyt-20200331.xsd	Edgar Link	pending
vcyt-20200331_cal.xml	Edgar Link	unprocessable
vcyt-20200331_def.xml	Edgar Link	unprocessable
vcyt-20200331_htm.xml	Edgar Link	completed
vcyt-20200331_lab.xml	Edgar Link	unprocessable
vcyt-20200331_pre.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$VCYT
Veracyte Inc Stock $vcyt

2020 Q1 Form 10-Q Financial Statement

#000138410120000058 Filed on May 06, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$VCYT Veracyte Inc Stock $vcyt

2020 Q1 Form 10-Q Financial Statement

#000138410120000058 Filed on May 06, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$VCYT
Veracyte Inc Stock $vcyt